Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 159

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 159
---
 failure to do so may result in the loss of all rights thereunder. Accordingly, each Dissenting Shareholder
who is considering exercising Dissent Rights should carefully consider and comply with the provisions of that section, the full text of which is set out in Annex C to this Circular and Proxy Statement, as modified by the Interim Order, the Plan of
Arrangement and any other order of the Court, and consult their own legal advisor as failure to strictly comply with the provisions of the QBCA (as modified or supplemented by the Interim Order, the Plan of Arrangement and any other order of the
Court) may prejudice Dissent Rights.

98

INTERESTS OF THE COMPANY’S DIRECTORS AND EXECUTIVE OFFICERS IN THE ARRANGEMENT Leadership of the Company Following the Arrangement As of the date hereof, none of the Company’s executive officers has entered into any new agreement, arrangement or understanding with the Purchaser or any of its affiliates regarding the terms and conditions of compensation, incentive pay or employment with the Company after the Arrangement. Although no agreements have been entered into at this time with any of the Company’s executive officers, prior to or following the completion of the Arrangement, they may enter into new agreements or amendments to existing arrangements with Parent or one of its affiliates regarding their employment with the Company after the Arrangement. As of the Effective Time, the then-current directors of the Company are expected to cease serving as directors except as otherwise determined by Parent. Other Interests of the Company’s Directors and Executive Officers in the Arrangement In considering the recommendations of the Board with respect to the Arrangement, Shareholders should be aware that the directors and executive officers of the Company have certain interests, including financial interests, in the Arrangement that may be different from, or in addition to, the interests of Shareholders generally. The Board was aware of these interests and considered them, among other matters, in approving the Agreement, and in making its recommendation that Shareholders approve the Arrangement. See “ The Arrangement — Background of the Arrangement” and “ The Arrangement — Recommendation of the Transaction Committee; Reasons for the Arrangement; Recommendation of the Board; and Opinion of Leerink Partners.” These interests are described in more detail further below, and certain of them are quantified in the narrative and the table below in “— Potential Change in Control Payments to Named Executive Officers.” As of the Record Date, the Company’s executive officers for purposes of the discussion below are as follows:

| Name                         |